Verve Therapeutics Cash Flow Statement

Financials in millions IDR. Fiscal year is January - December.

Millions IDR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	9,291	8,701	2,729
Depreciation & Amortization	806.08	652.61	787.18
Other Operating Activities	11.14	-2,755	2,984
Operating Cash Flow	10,108	6,599	6,501
Operating Cash Flow Growth	53.17%	1.52%	-
Capital Expenditures	-1,412	-673.75	-238.65
Sale of Property, Plant & Equipment	1.25	0.5	-
Other Investing Activities	3,486	-726.51	-5,973
Investing Cash Flow	2,075	-1,400	-6,212
Issuance of Common Stock	9,490	-	-
Common Dividends Paid	-13,668	-6,530	-
Other Financing Activities	-0.02	-0.02	0
Financing Cash Flow	-4,178	-6,530	0
Net Cash Flow	8,004	-1,331	288.78
Free Cash Flow	8,695	5,925	6,262
Free Cash Flow Growth	46.75%	-5.38%	-
Free Cash Flow Margin	24.28%	21.54%	35.77%
Free Cash Flow Per Share	151.50	145.23	153.48
Cash Income Tax Paid	299.27	137.95	99.21
Levered Free Cash Flow	1,524	3,364	-
Unlevered Free Cash Flow	1,549	3,364	-
Change in Net Working Capital	3,391	2,001	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.